Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy

NCT Number	NCT07215962
Lead Sponsor	Bristol-Myers Squibb
Conditions	Non-small Cell Lung Cancer (NSCLC)
Enrollment	300 participants
Start Date	2024-11-22
Primary Completion	2025-07-01 (estimated)
Study Completion	2026-03-01 (estimated)
Updated on ClinicalTrials.gov	2025-10-14